The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 8-11 September 2014. Topics discussed at the meeting:
- PRAC concludes review of Valdoxan/Thymanax (agomelatine).
- Two years of focus on patient safety.
- One month left to respond to the consultation on public hearings.
Read PRAC's monthly report from the meeting 8-11 September 2014